Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2020 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress

Four abstracts from the OV101 (gaboxadol) clinical development program in Angelman Syndrome and Fragile X Syndrome to be presented NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics...
September 30, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies

Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency...
September 11, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
August 25, 2020 07:50 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare...
August 25, 2020 07:00 ET | Source: Ovid Therapeutics Inc.

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome...
August 10, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020Multiple data readouts for soticlestat expected in Q3 2020,...
August 05, 2020 09:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
July 23, 2020 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing...
July 14, 2020 18:01 ET | Source: Ovid Therapeutics Inc.

A Ovid Therapeutics e a Angelini Pharma celebram um acordo de licença exclusivo para desenvolver, fabricar e comercializar o medicamento OV101 para o tratamento da síndrome de Angelman na Europa

A Angelini Pharma obtém os direitos exclusivos de desenvolvimento, fabricação e comercialização do OV101 (gaboxadol) para o potencial tratamento da síndrome de Angelman na União Europeia, outros...
July 14, 2020 18:01 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics und Angelini Pharma schließen exklusive Lizenzvereinbarung zur Entwicklung, Herstellung und Vermarktung von OV101 zur Behandlung des Angelman-Syndroms in Europa ab

Angelini Pharma erhält Exklusivrechte für die Entwicklung, Herstellung und Vermarktung von OV101 (Gaboxadol) zur potenziellen Behandlung des Angelman-Syndroms in der Europäischen Union und anderen...